Literature DB >> 24139354

Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.

Aruna V Sarma1, Jennifer L St Sauver2, Debra J Jacobson3, Michaela E McGree3, George G Klee4, Michael M Lieber5, Cynthia J Girman6, John M Hollingsworth7, Steven J Jacobsen8.   

Abstract

OBJECTIVE: To determine the distribution of, and racial differences in, changes in prostate-specific antigen (PSA) from a population-based sample of men.
MATERIALS AND METHODS: Data from 2 prospective cohort studies of a random sample of white men, aged 40-79 years in 1990, followed biennially through 2007, and African American men, aged 40-79 years in 1996, followed through 2000, were examined to assess the longitudinal changes in PSA concentrations. Serum PSA levels were determined at each examination for both cohorts and observations after a diagnosis of prostate cancer or treatment of benign prostatic hyperplasia were censored. The observed and estimated annual percentage of change in the serum PSA levels were examined by race.
RESULTS: At baseline, the median PSA level in the white men did not differ from the median level observed in the African American men (white men 0.9 ng/mL; African American men 0.9 ng/mL; P = .48). However, African American men had a much more rapid increase in the PSA level over time compared with the white men (median annual percent change in PSA for white men 3.6%/y, African American men 7.9%/y; P <.001).
CONCLUSION: These data suggest that African American men have more rapid rates of change in the PSA levels over time. If the difference in the rate of changes between African American and white men is an early indicator of future prostate cancer diagnosis, earlier detection in African American men could help to alleviate the racial disparities in prostate cancer diagnosis and mortality.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24139354      PMCID: PMC3896508          DOI: 10.1016/j.urology.2013.08.025

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  30 in total

1.  Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Authors:  Andreas P Berger; Martina Deibl; Hannes Steiner; Jasmin Bektic; Alexandre Pelzer; Robert Spranger; Helmut Klocker; Georg Bartsch; Wolfgang Horninger
Journal:  Prostate       Date:  2005-08-01       Impact factor: 4.104

2.  Families of lines: random effects in linear regression analysis.

Authors:  H A Feldman
Journal:  J Appl Physiol (1985)       Date:  1988-04

3.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

4.  Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.

Authors:  R J Henderson; J A Eastham; D J Culkin; M W Kattan; T Whatley; J Mata; D Venable; O Sartor
Journal:  J Natl Cancer Inst       Date:  1997-01-15       Impact factor: 13.506

5.  Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.

Authors:  J W Moul; R R Connelly; R M Mooneyhan; W Zhang; I A Sesterhenn; F K Mostofi; D G McLeod
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

6.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

7.  The prevalence of prostatism: a population-based survey of urinary symptoms.

Authors:  C G Chute; L A Panser; C J Girman; J E Oesterling; H A Guess; S J Jacobsen; M M Lieber
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

8.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

9.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

10.  Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.

Authors:  H B Carter; J D Pearson; Z Waclawiw; E J Metter; D W Chan; H A Guess; P C Walsh
Journal:  Urology       Date:  1995-04       Impact factor: 2.649

View more
  2 in total

1.  What explains the differences between centres in the European screening trial? A simulation study.

Authors:  Jaakko Nevalainen; Ulf-Håkan Stenman; Teuvo L Tammela; Monique Roobol; Sigrid Carlsson; Kirsi Talala; Fritz H Schröder; Anssi Auvinen
Journal:  Cancer Epidemiol       Date:  2016-11-24       Impact factor: 2.984

2.  Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.

Authors:  Yong Hyun Park; In Young Choi; Sei Chul Yoon; Hong Seok Jang; Hyong Woo Moon; Sung-Hoo Hong; Sae Woong Kim; Tae-Kon Hwang; Ji Youl Lee
Journal:  Prostate Int       Date:  2015-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.